1887

14 : Bioterrorist Threats: What the Infectious Disease Community Should Know about Anthrax and Plague

Author: Thomas V. Inglesby1
VIEW AFFILIATIONS HIDE AFFILIATIONS
Affiliations: 1: Johns Hopkins Center for Civilian Biodefense Studies, 111 Market Place, Suite 850, Baltimore, MD 21202-6709
Content Type: Monograph
Publication Year: 2001

Category: Clinical Microbiology

MyBook is a cheap paperback edition of the original book and will be sold at uniform, low price.

Preview this chapter:
Preview Magnify
Zoom in
Zoomout

Bioterrorist Threats: What the Infectious Disease Community Should Know about Anthrax and Plague, Page 1 of 2

| /docserver/preview/fulltext/10.1128/9781555816988/9781555812164_Chap14-1.gif /docserver/preview/fulltext/10.1128/9781555816988/9781555812164_Chap14-2.gif

Abstract:

This chapter addresses the following questions: If anthrax or plague were used as a biological weapon, what would be the expected epidemiology? What would be the clinical manifestations? How would a diagnosis be made? What is the recommended treatment? And what is the role of vaccination? Anthrax and plague are widely and appropriately considered two of the most serious potential biological weapons. A World Health Organization analysis of 1970 described the destructive capacity of anthrax and plague. Inhalational anthrax is the least common important manifestation of the naturally occurring form of this disease. A national working group called the Working Group on Civilian Biodefense has published consensus guidelines on the treatment and public health management of anthrax and plague as biological weapons. Given that the chance for survival from inhalational anthrax diminishes with time after symptom onset, antibiotic prophylaxis is advised as early as possible. Secondary pneumonic plague occurs as often as 10 to 12% of the time following primary bubonic or septicemic plague. This chapter concludes by stating that it is clear that the technology supporting the development of mass casualty- producing biological weapons has existed for some time and is now becoming more accessible and less expensive. It is clear that biological weapons have the potential to cause tremendous illness and death. Thus it is evident that infectious diseases specialists and the broader biological sciences community have the responsibility to engage in the challenges posed by biological weapons.

Citation: Inglesby T. 2001. Bioterrorist Threats: What the Infectious Disease Community Should Know about Anthrax and Plague, p 223-234. In Scheld W, Craig W, Hughes J (ed), Emerging Infections 5. ASM Press, Washington, DC. doi: 10.1128/9781555816988.ch14
Highlighted Text: Show | Hide
Loading full text...

Full text loading...

References

/content/book/10.1128/9781555816988.chap14
1. Abramova, F. A.,, L. M. Grinberg,, O. Yampolskaya,, and D. H. Walker. 1993. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak in 1979. Proc. Natl. Acad. Sci. USA 90: 2291– 2294.
2. American Public Health Association. 1995. Anthrax, p. 18– 22. In A. S. Benenson (ed.), Control of Communicable Diseases, 17th ed. American Public Health Association, Washington, D.C.
3. Bell, J. H. 1880. On “Woolsorter's disease.” Lancet 5 June: 871– 873.
4. Brachman, P. S.,, and A. Friedlander,. 1999. Anthrax, p. 629– 637. In S. A. Plotkin, and W. A. Orenstein (ed.), Vaccines, 3rd ed. The W. B. Saunders Co., Philadelphia, Pa.
5. Brachman, P. S. 1980. Inhalation anthrax. Ann. N. Y. Acad. Sci. 353: 83– 93.
6. Brachman, P. S.,, H. Gold,, S. A. Plotkin,, F. R. Fekety,, M. Werrin,, and N. R. Ingraham. 1962. Field evaluation of human anthrax vaccine. Am. J. Public Health 52: 632– 645.
7. Butler, T., 1991. Plague, p. 408– 416. In G. T. Strickland (ed.), Tropical Medicine. The W. B. Saunders Co., Philadelphia, Pa.
8. Centers for Disease Control and Prevention. 1999. Critical Biological Agents for Public Health Preparedness: Summary of Selection Process and Recommendations. October 16. Centers for Disease Control and Prevention, Atlanta, Ga.
9.Centers for Disease Control and Prevention. 1997. Fatal human plague. Morb. Mortal. Wkly. Rep. 278: 380– 382.
10.Centers for Disease Control and Prevention. 1996. Prevention of plague. Morb. Mortal. Wkly. Rep. 4(RR-14): S– 15.
11. Centers for Disease Control and Prevention. 1994. Summary of notifiable diseases, 1945-1994. Morb. Mortal. Wkly. Rep. 43: 70– 78.
12. Chen, T. H., 1986. Yersinia, Pasteurella and Francisella, p. 333– 345. In A. I. Braude,, C. E. Davis,, and J. Fierer (ed.), Infectious Diseases and Medical Microbiology. The W. B. Saunders Co., Philadelphia, Pa.
13.. Dixon, T. C.,, M. Meselson,, J. Guillemin,, and P. C. Hanna. 1999. Anthrax. N. Engl. J. Med. 341: 815– 826.
14. Friedlander, A.,, S. L. Welkos,, and M. L. Pitt. 1993. Postexposure prophylaxis against experimental inhalation anthrax. J. Infect. Dis. 167: 1239– 1242.
15. Garrett, L. 2000. Betrayal of Trust: The Collapse of Global Public Health, p. 15– 49. Hyperion, New York, N.Y.
16. Inglesby, T. V.,, D. A. Henderson,, J. G. Bartlett,, M. S. Ascher,, E. Eitzen,, A. M. Friedlander,, J. Hauer,, J. McDade,, M. T. Osterholm,, T. O'Toole,, G. Parker,, T. M. Perl,, P. K. Russell,, and K. Tonat. 1999. Anthrax as a biological weapon: medical and public health management. JAMA 281: 1735– 1745.
17. Inglesby, T. v.,, D. T. Dennis,, D. A. Henderson,, J. G. Bartlett,, M. S. Ascher,, E. Eitzen,, A. D. Fine,, A. M. Friedlander,, J. Hauer,, J. F. Koerner,, M. Layton,, J. McDade,, M. T. Osterholm,, T. O'Toole,, G. Parker,, T. M. Perl,, P. K. Russell,, and M. Schoch-Spana. 2000. Plague as a biological weapon: medical and public health management. JAMA 283: 2281– 2290.
18. Institute of Medicine, National Research Council. 1995. Chemical and Biological Terrorism: Research and Development to Improve Civilian Medical Response, p. 95. National Academy Press, Washington, D.C.
19. Kipple, K. F. 1993. Cambridge World History of Human Disease. Cambridge University Press, New York, N.Y.
20. Kohout, E.,, A. Sehat,, and M. Ashraf. 1964. Anthrax: a continuous problem in southwest Iran. Am.J. Med. Sci. 247: 565.
21. Meselson, M.,, J. Guillemin,, M. Hugh-Jones,, A. Langmuir,, I. Popova,, A. Shelokov,, and O. Yampolskaya. 1994. The Sverdlovsk anthrax outbreak of 1979. Science 266: 1202– 1208.
22. Meyer, K. 1961. Pneumonic plague. Bacteriol. Rev. 25: 249– 261.
23. Michigan Department of Public Health. 1978. Anthrax Vaccine Absorbed. Michigan Department of Public Health, Lansing.
24. Miller, J. M.,, and W. Broad. 1998. Germ weapons: in Soviet past or in the new Russia's future? New York Times, December 27, p. 1, 11.
25. Morse, S.,, and J. McDade. 1994. Recommendations for working with pathogenic bacteria. Methods Enzymol. 235: 1– 26.
26. Office of Technology Assessment,U.S. Congress. 1993. Proliferation of Weapons of Mass Destruction, p. 53– 55. Publication OTA-ISC-559. U.S. Government Printing Office, Washington, D.C.
27. Perry, R. D.,, and J. D. Fetherston. 1997. Yersinia pestis-etiologic agent of plague. Clin. Microbiol. Rev. 10: 35– 66.
28. Slack, P. 1989. The black death past and present: some historical problems. Trans. R. Soc. Trop. Med. Hyg. 83: 461– 463.
29. Vessal, K.,, J. Yeganehdoust,, W. Dutz,, and E. Kohout. 1975. Radiologic changes in inhalation anthrax: a report of radiological and pathological correlation in two cases. Clin. Radiol. 26: 471– 474.
30. Voroboyov, A. 1994. "Criterion rating" as a measure of probable use of bioagents as biological weapons. Presented to the Working Group on Biological Weapons Control, Committee on International Security and Arms Control, National Academy of Sciences, Washington, D.C.
31. Williams, P.,, and D. Wallace. 1989. Unit 731: Japan's Secret Biological Warfare in World War II, p. 69– 70. The Free Press, New York, N.Y.
32. Williams, R. P., 1986. Bacillus anthracis and other spore forming bacilli, p. 270– 278. In A. I. Braude,, L. E. Davis,, and J. Fierer (ed.), Infectious Diseases and Medical Microbiology. The W. B. Saunders Co., Philadelphia, Pa.
33. Wilmoth, B. A.,, M. C. Chu,, and T. C. Quan. 1996. Identification of Yersinia pestis by BBL Crystal Enteric/Nonfermenter Identification System. J. Clin. Microbiol. 34: 2829– 2830.
34. World Health Organization. 1970. Health Aspects of Chemical and Biological Weapons, p. 98– 99. World Health Organization, Geneva, Switzerland.
35. Wu, L.-T. 1926. A Treatise on Pneumonic Plague, p. 296. League of Nations, Geneva, Switzerland.
36. Zilinskas, R. A. 1997. Iraq's biological weapons: the past as future? JAMA 278: 418– 424.

Tables

Bioterrorist Threats: What the Infectious Disease Community Should Know about Anthrax and Plague
[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/author/10.1128/9781555816988.chap14-1,webId=/content/author/10.1128/9781555816988.chap14-1,properties={foaf_givenname=Thomas V., foaf_name=Thomas V. Inglesby, foaf_surname=Inglesby, pub_isAffiliatedWith=[com.pub2web.rdf.cci.facet.ContentItem[id=http://asm.metastore.ingenta.com/content/affiliation/10.1128/9781555816988.chap14-aff1]]}]]
Citation: Inglesby T. 2001. Bioterrorist Threats: What the Infectious Disease Community Should Know about Anthrax and Plague, p 223-234. In Scheld W, Craig W, Hughes J (ed), Emerging Infections 5. ASM Press, Washington, DC. doi: 10.1128/9781555816988.ch14
/content/10.1128/9781555816988.chap14.tab14-1
Table 1

Anthrax and plague following use of a biological weapon

10.1128/9781555816988/tab14-1_thmb.gif
10.1128/9781555816988/tab14-1.gif
Generic image for table
Table 1

Anthrax and plague following use of a biological weapon

Citation: Inglesby T. 2001. Bioterrorist Threats: What the Infectious Disease Community Should Know about Anthrax and Plague, p 223-234. In Scheld W, Craig W, Hughes J (ed), Emerging Infections 5. ASM Press, Washington, DC. doi: 10.1128/9781555816988.ch14

Back to top
This is a required field
Please enter a valid email address
Please check the format of the address you have entered.
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error